Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
39 hedge funds and large institutions have $19.1M invested in Sio Gene Therapies Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 23 closing their positions.
19% more call options, than puts
Call options by funds: $3.86M | Put options by funds: $3.25M
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
32% less funds holding
Funds holding: 57 → 39 (-18)
60% less capital invested
Capital invested by funds: $48.4M → $19.1M (-$29.3M)
78% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 23
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.16M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.93M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$442K |
| 4 |
Jane Street
New York
|
+$319K |
| 5 |
SIM
Spark Investment Management
New York
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$8.16M |
| 2 |
DM
Deerfield Management
New York
|
-$5.28M |
| 3 |
JG
Jefferies Group
New York
|
-$3.35M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.93M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.73M |
SIOX Hedge Fund Activity: Q2 2019 in Review
39 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2019, worth a combined $19.1M — down 60% from $48.4M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SIOX and 5 opened new positions — a net loss of 18 holders — while 17 trimmed existing stakes and 12 added.
The largest buyer was Citadel Advisors, adding an estimated $3.16M. The largest seller was CVI Holdings, exiting entirely with an estimated $8.16M sold.
- 39 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2019, down from 57 in Q1 2019.
- Funds reported $19.1M of Sio Gene Therapies Inc. Common Stock stock for Q2 2019, down 60% quarter-over-quarter.
- 5 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2019 and 23 closed out, a net change of -18 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2019 was Citadel Advisors, an estimated $3.16M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2019 was CVI Holdings, an estimated $8.16M sold.
Based on aggregated 13F filings for Q2 2019.